본문 바로가기
KERD
논문KCI 등재

유방암 환자의 항암화학요법 후 한방병원 입원치료에 대한 일개 한방병원 환자 특성 및 치료 고찰

Analysis of the Patients and Treatment of Korean Medicine Hospital after Chemotherapy in Patients with Breast Cancer

김선경|강수진|양금진|홍가경|조한백
대한한방부인과학회 (The Society Of Oriental Obstetrics & Gynecology)|2020.05|대한한방부인과학회지 (The Journal of Oriental Obstetrics ＆ Gynecology)|제33권 제2호|pp. 77-89|DOI https://doi.org/10.15204/jkobgy.2020.33.2.077

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Herbal MedicineKorean Traditional MedicineBreast CancerChemotherapyBreast Neoplasm
주제분류한의학

초록

Objectives: The purpose of this study is to analyse current status and treatment of the Korean medicine hospital after chemotherapy in patients with breast cancer. Methods: We investigated the medical records of 21 patients who admitted to Korean medicine hospital after chemotherapy in patients with breast cacner from March 1, 2017 to December 31, 2019. We searched medical records retrospectively and analyzed current status and treatment of Korean medicine hospital. Results: The average age of 21 participants was 52.81±8.38 years and 40s and 50s accounted for 85.6% of the total. After receiving chemotherapy, the average time to hospitalization was 1.87±3.13days and average hospital stay was 9.78±4.14 days. The subjects were classified as 28.6% of stage I, 52.4% of stage Ⅱ, 9.5% of stage Ⅲ, and 9.5% of stage Ⅳ. The analysis according to the presence of metastasis was 57.1% without metastasis, 33.3% with axillary lymph node metastasis, and 9.5% with distant metastasis. The main symptoms complained when hospitalized by 21 subjects were nausea (54.2%), fatigue (54.2%), and anorexia (50.8%) in over 50%, pantalgia (47.5%), and insomnia (47.5%), dizziness (44.1%), cold sweating (42.4%), lower extremity pain (40.7%), 37.5~37.9℃ fever (39.0%), headache (37.3%), hot flush (37.3%), pruritus (30.5%) are 30% or more. Korean medicine treatment was performed in 87.4% of all hospitalizations and Gwakhyangjunggi-san-gami was the most administered prescription. Extracts of Korean medicine was performed in 100.0% of all patients and Eunkyo-san was most administered extracts medicine. Acupuncture, moxibustion, and cupping treatments were performed in all 21 study subjects. Other treatments was performed at a frequency of hyperthermia (90.5%), lymph massage (23.8%), air compression therapy (23.8%), and Interference current therapy (19.0%) Conclusion: Korean traditional medicine can be used as a countermeasure for side effects after chemotherapy in breast cancer patients.

Abstract

Objectives: The purpose of this study is to analyse current status and treatment of the Korean medicine hospital after chemotherapy in patients with breast cancer. Methods: We investigated the medical records of 21 patients who admitted to Korean medicine hospital after chemotherapy in patients with breast cacner from March 1, 2017 to December 31, 2019. We searched medical records retrospectively and analyzed current status and treatment of Korean medicine hospital. Results: The average age of 21 participants was 52.81±8.38 years and 40s and 50s accounted for 85.6% of the total. After receiving chemotherapy, the average time to hospitalization was 1.87±3.13days and average hospital stay was 9.78±4.14 days. The subjects were classified as 28.6% of stage I, 52.4% of stage Ⅱ, 9.5% of stage Ⅲ, and 9.5% of stage Ⅳ. The analysis according to the presence of metastasis was 57.1% without metastasis, 33.3% with axillary lymph node metastasis, and 9.5% with distant metastasis. The main symptoms complained when hospitalized by 21 subjects were nausea (54.2%), fatigue (54.2%), and anorexia (50.8%) in over 50%, pantalgia (47.5%), and insomnia (47.5%), dizziness (44.1%), cold sweating (42.4%), lower extremity pain (40.7%), 37.5~37.9℃ fever (39.0%), headache (37.3%), hot flush (37.3%), pruritus (30.5%) are 30% or more. Korean medicine treatment was performed in 87.4% of all hospitalizations and Gwakhyangjunggi-san-gami was the most administered prescription. Extracts of Korean medicine was performed in 100.0% of all patients and Eunkyo-san was most administered extracts medicine. Acupuncture, moxibustion, and cupping treatments were performed in all 21 study subjects. Other treatments was performed at a frequency of hyperthermia (90.5%), lymph massage (23.8%), air compression therapy (23.8%), and Interference current therapy (19.0%) Conclusion: Korean traditional medicine can be used as a countermeasure for side effects after chemotherapy in breast cancer patients.

참고문헌 (37)

  1. "National Cancer Registration Statistics"[URL]
  2. Paik N, "Current Status of Breast Cancer in Korea", Ewha Med J, 37(2), pp.69~74 (2014)
  3. Ahn JH, "Systemic adjuvant therapy in breast cancer", Korean J Med, 69(3), pp.243~254 (2005)
  4. 박수경, "한국인에서 유방암의 역학적 특성", 대한의사협회지, 62(8), pp.424~436 (2019), 대한의사협회
  5. Broeckel JA, "Quality of life after adjuvant chemotherapy for breast cancer", Breast Cancer Res Treat, 62(2), pp.141~150 (2000)
  6. Partridge AH, "Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer", J Natl Cancer Inst Monogr, 2001(30), pp.135~142 (2001)
  7. Cassileth BR, "The Prevalence of Complementary", Alternative A Systematic Review, 1998, pp.83(4), 777~782
  8. 한솔아, "유방암 환자의 항암 치료 부작용 및 한의학적 보완치료 경험에 관한 포커스 그룹 연구", 대한한방부인과학회지, 30(1), pp.85~94 (2017), 대한한방부인과학회[DOI]
  9. 박지혜, "전자침술로 호전된 유방암 환자의 항암화학요법 유발 말초신경병증 증례보고", 대한암한의학회지, 20(1), pp.1~9 (2015), 대한암한의학회
  10. 한가진, "유방암에 대한 한양방 병용 치료 증례 보고 1례", 대한한방내과학회지, 38(5), pp.820~827 (2017), 대한한방내과학회
  11. 한가진, "진행성 유방암에 대한 한양방 병용 치료 치험 1례", 대한한방내과학회지, 39(2), pp.268~276 (2018), 대한한방내과학회
  12. 박병록, "한방치료를 통해 Adriamycin", Cytoxan 및 Taxol 항암제 부작용이 감소한 유방암 환자 증례보고, 2011, pp.32(3), 451~457[DOI]
  13. Kim SH, "Chemotherapy of Breast Cancer", Korean J Med, 58(5), pp.497~509 (2000)
  14. 강은영, "The Korean Hereditary Breast Cancer Study: Review and Future Perspectives", Journal of Breast Cancer, 16(3), pp.245~253 (2013), 한국유방암학회
  15. Watson GW, "Breast cancer;a new approach to therapy", Br Med J, 1(5133), pp.1315~1320 (1959)
  16. Lee A, "Chemotherapy in Breast Cancer", Ewha Med J, 37(2), pp.75~82 (2014)
  17. 박진희, "보조적 항암요법을 받는 유방암 환자의 증상 경험 및 삶의 질의 변화", Asian Oncology Nursing, 15(2), pp.67~74 (2015), 대한종양간호학회
  18. Breast Cancer Facts & Figures, "Oh SJ", Korean Breast Cancer Society, 10~ (2019)
  19. 강현석, "한국 여성에서 신체질량지수와 유방암 발생과의 관련성에 대한 연구", Journal of Breast Disease, 4(2), pp.64~69 (2016), 한국유방암학회[DOI]
  20. Charles L, "Side effects of Adjuvant Treatment of Breast Cancer", N Engl J Med, 344(26), pp.1997~2008 (2001)
  21. Saibil S, "Incidence of taxaneinduced pain and distress in patients receiving chemotherapy for early-stage breast cancer : A retrospective, outcomes-based survey", Curr Oncol, 17(4), pp.42~47 (2010)
  22. 주은실, "항암화학요법을 받은 유방암환자의호중구 감소증 발생실태와 영향요인", 한국산학기술학회논문지, 19(6), pp.519~525 (2018), 한국산학기술학회[DOI]
  23. Jin KP, "Taepyeonghyeminhwajegukbang. 1", pp.53~ (1996), China Press of Traditional Chinese Medicine
  24. Kim SC, "Bangjehak. 4", pp.488~490 (1999), Yeonglimsa
  25. Liu Y, "Effect of Huoxiangzhengqi Powder on Immune and Metabolic Function of Sub-healthy Animals with Dampness, Spleen and Stomach", Lishizhen Med Mater medica Res, 22(5), pp.1190~1192 (2011)
  26. Liu Y, "Protective effect of huoxiang zhengqi oral liquid on intestinal mucosal mechanical barrier of rats with postinfectious irritable bowel syndrome induced by acetic acid", Evidence-based Complement Altern Med, 2014, pp.1~10 (2014)
  27. Viaud S, "The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide", Science, 342(6161), pp.971~976 (2013)
  28. Zitvogel L, "Microbiome and Anticancer Immunosurveillance", Cell, 165(2), pp.276~287 (2016)
  29. Routy B, "The gut microbiota influences anticancer immunosurveillance and general health", Nat Rev Clin Oncol, 15(6), pp.382~396 (2018)
  30. Viaud S, "Gut microbiome and anticancer immune response: Really hot Sh*t!", Cell Death Differ, 22(2), pp.199~214 (2015)
  31. Oh KT, "Onbyeongjobyeon. 1", pp.94~99 (2004), Jipmundang
  32. Kim SC, "Bangjehak. 4", pp.83~84 (1999), Yeonglimsa
  33. Li Z, "Immune-Regulating Effect of Yinqiao Powder in Different Decocted Time on Rats with Immune Suppression", J Tradit Chinese Med, 49(12), pp.1112~1115 (2008)
  34. Fu YJ, "Effects of different principles of Traditional Chinese Medicine treatment on TLR 7", NF-κB signaling pathway in influenza virus infected mice, 2018, pp.13(1), 1~16
  35. Dundee JW, "Acupuncture prophylaxis of cancer chemotherapy-induced sickness", J R Soc Med, 82(5), pp.268~271 (1989)
  36. Molassiotis A, "Acupuncture for cancer-related fatigue in patients with breast cancer : A pragmatic randomized controlled trial", J Clin Oncol, 30(36), pp.4470~4476 (2012)
  37. Ben-Horin I, "Acupuncture and Reflexology for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer", Integr Cancer Ther, 16(3), pp.258~262 (2017)

관련 논문AI추천

한방 입원치료를 통해 항암화학요법 후 발생한 부작용이 개선된 유방암 환자 6례김규태, 박남경, 박승혁, 이진무, 이창훈, 장준복, 황덕상, 황영식대한한방부인과학회 · 대한한방부인과학회지2020 · 제33권 제2호일개 한방병원에 내원한 유방암 환자의 특성 및 치료 분석김규태, 박승혁, 이진무, 이진욱, 이창훈, 장준복, 황덕상, 황영식대한한방부인과학회 · 대한한방부인과학회지2019 · 제32권 제4호유방암에 대한 한양방 병용 치료 증례 보고 1례성신, 김성수, 이아람, 정준석, 한가진대한한방내과학회 · 대한한방내과학회지2017 · 제38권 제5호한방치료를 통해 Adriamycin/Cytoxan 및 Taxol 항암제 부작용이 감소한 유방암 환자 증례보고박병록, 박재우, 유화승, 이연월, 조종관대한한방내과학회 · 대한한방내과학회지2011 · 제32권 제3호한의표준임상진료지침 개발을 위한 유방암 보완치료 실태조사강나훈, 김남훈, 박경선, 박남춘, 유은실, 이진무, 이진욱, 이창훈, 장보형, 장준복, 황덕상대한한방부인과학회 · 대한한방부인과학회지2018 · 제31권 제4호한방병원에 내원한 유방암 및 부인암 환자 58명에 대한 임상적 특성 분석김경순, 김승모, 박수완, 주정현, 최홍식한의병리학회 · 동의생리병리학회지2014 · 제28권 제5호

이 간행물의 다른 논문 (8건)

전탕시간에 따른 애엽의 성분패턴 비교연구김민선, 황덕상, 이창훈, 장준복, 이진무, 한성민, 윤준걸pp. 1-12자궁근종의 한약치료에 대한 최신 임상 연구 동향 -CNKI 검색을 중심으로김보리, 최유진, 양승정, 조성희pp. 13-28재발성 칸디다성 외음질염의 한약치료 효과에 관한 무작위 대조 연구 문헌고찰이진무, 장준복, 이창훈, 황덕상, 박승혁, 채민수pp. 29-43자궁경부 상피내종양의 환상투열요법 후 한약치료의 효과 : 체계적 문헌고찰 및 메타분석이창훈, 황덕상, 이수정, 지해리, 이혜정, 장준복, 이진무pp. 44-62출산 후 산모들의 주관적인 신체 평가에 대한 연령과 분만방식에 따른 분석하수진, 이진무, 장준복, 이창훈, 황덕상pp. 63-76
원문 보기